Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical
  • Published:

Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia

British Journal of Cancer volume 86, pages 31–35 (2002)Cite this article

Abstract

To assess the relative merit of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in predicting the risk of disease progression of patients with early B-cell chronic lymphocytic leukaemia we analyzed 81 Binet stage A patients whose sera were taken at the time of diagnosis and evaluated for the presence of vascular endothelial growth factor and basic fibroblast growth factor using an enzyme-linked immunosorbent assay. Serum levels of vascular endothelial growth factor positively correlated with Rai sub-stages (P=0.03), peripheral blood lymphocytosis (P=0.03), bone marrow histology (P=0.04) and β2-microglobulin (β2-m) (P=0.006). When dealing with basic fibroblast growth factor only a correlation with Rai sub-stages (P=0.02) could be found. Different cut-offs set on the basis of a stratification in quartiles, failed to demonstrate any correlation between serum levels of basic fibroblast growth factor and disease progression. In contrast, patients with increased serum levels of vascular endothelial growth factor (above median value, 203 pg ml−1) had a three times increased risk of disease progression, although, in multivariate analysis only Rai sub-stages (P=0.0001) and lymphocyte doubling time (P=0.002) retained their prognostic significance. Low levels of vascular endothelial growth factor were indicative of good clinical outcome in the subgroup of patients with either low (P=0.02) or high (P=0.03) β2-m concentration. Finally, the highest prognostic power was obtained when serum vascular endothelial growth factor and β2-m were examined in combination. Median of progression-free survival of patients who had both serum vascular endothelial growth factor and β2-m higher than median value was only 13 months, in contrast median progression-free survival of patients with one marker increased (i.e. above the 50th percentile) was 40 months. Patients with both markers below the median experienced the best clinical outcome (median progression-free survival not reached at 40 months). In conclusion, serum levels of either vascular endothelial growth factor or basic fibroblast growth factor are high in patients with early chronic lymphocytic leukaemia, however, only vascular endothelial growth factor predicts behaviour of disease and helps to refine the prognosis of stage A patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

References

  • Aguayo A, O'Brien S, Keating M, Manshouri T, Gidel C, Barlogie B, Beran M, Koller C, Kantarjian H, Albitar M (2000) Clinical relevance of vascular endothelial growth factor levels in B-cell chronic lymphocytic leukaemia. Blood 96: 768–770

    CAS  PubMed  Google Scholar 

  • Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walter C, Selby PJ (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77: 956–964

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Coasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tohernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198–212

    Article  CAS  PubMed  Google Scholar 

  • Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR (1996) National Institute-sponsored working group guidelines for chronic lymphocytic leukemia: guidelines for diagnosis and treatment. Blood 87: 4990–4997

    CAS  PubMed  Google Scholar 

  • Damle RN, Wasil T, Fais F et al (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840–1847

    CAS  PubMed  Google Scholar 

  • Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, De Pooter C, Van Oosterom AT (1996) Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 7: 843–848

    Article  CAS  PubMed  Google Scholar 

  • Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoyl I, De Pooter C, Martin M, Van Oosterom AT (1997) Elevated levels of the angiogenic cytokines basic fibroblast growth factor in sera of cancer patients. Br J Cancer 76: 238–243

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dohner H, Stilgenbauer S, Brenner A, Leupolt E, Bullinger L, Dohner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910–1916

    Article  CAS  PubMed  Google Scholar 

  • Fuhrmann-Benzakein E, Ma MN, Rubbia-Brandt L, Mentha G, Ruefenatch D, Sappino AP, Pepper MS (2000) Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 85: 40–48

    Article  CAS  PubMed  Google Scholar 

  • Hamblin TJ, Davis Z, Gadiner A, Oscier DG, Stevenson FK (1999) Umnutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848–1854

    CAS  PubMed  Google Scholar 

  • Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM, Albitar M (2001) CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98: 181–186

    Article  CAS  PubMed  Google Scholar 

  • Kini AR, Kay NE, Peterson LC (2000) Increased bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 14: 1414–1418

    Article  CAS  PubMed  Google Scholar 

  • Kitamura M, Toi M, Arai K, Iwasaki Y, Suzuki H, Matsno K (1998) Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients. Oncol Rep 5: 1419–1424

    CAS  PubMed  Google Scholar 

  • Konig A, Menzel T, Linsen S, Wrazel I, Rosen A, Al-Kabit A, Raveche E, Gabrilove JL (1997) Basic fibroblastic growth factor (b-FGF) upregulates the expression of bcl-2 in B-cell chronic lymphocytic leukaemia cell lines resulting in delaying apoptosis. Leukemia 11: 258–265

    Article  CAS  PubMed  Google Scholar 

  • Kumar H, Heer K, Lee PW, Duthie GS, MacDonald AW, Greeman J, Kerin MJ, Monson JRT (1998) Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 4: 1279–1285

    CAS  PubMed  Google Scholar 

  • Leunig A, Tauber S, Spaett R, Grevers G, Leuning M (1998) Basic fibroblast growth factor in serum and urine of patients with head and neck cancer. Oncol Rep 5: 955–958

    CAS  PubMed  Google Scholar 

  • Menzel T, Rahaman Z, Calleja P, White K, Wilson FL, Wieder R, Gabrilove J (1996) Elevated intracellular levels of basic fibroblastic growth factor correlate with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabina. Blood 87: 1056–1063

    CAS  PubMed  Google Scholar 

  • Molica S (1991) Progression survival studies in early chronic lymphocytic leukemia. Blood 78: 895–899

    CAS  PubMed  Google Scholar 

  • Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V (1999) Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 107: 605–610

    Article  CAS  PubMed  Google Scholar 

  • Molica S (2001) Prognostic factors in chronic lymphocytic leukemia. InChronic Lymphoid Leukemias Second Edition, Revised and Expanded, Cheson BD (ed) pp231–260., New York: Marcel Dekker

    Google Scholar 

  • Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C (1986) Lymphocyte doubling time in chronic lymphocytic leukemia: analysis of its prognostic significance. Br J Haematol 62: 567–578

    Article  CAS  PubMed  Google Scholar 

  • O'Brien TS, Smith K, Cranston D, Fuggle S, Bicknell R, Harris AL (1995) Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Br J Urol 76: 311–314

    Article  CAS  PubMed  Google Scholar 

  • Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy NR, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46: 219–234

    CAS  PubMed  Google Scholar 

  • Rozman C, Montserrat E, Rodriguez-Fernandez JM et al (1984) Bone marrow histologic pattern: the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 64: 642–653

    CAS  PubMed  Google Scholar 

  • Salven P, Manpaa H, Orpana H, Alitalo K, Joensuu H (1997a) Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 3: 647–651

    CAS  PubMed  Google Scholar 

  • Salven P, Teerenhovi L, Joensuu H (1997b) A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 90: 3167–3172

    CAS  PubMed  Google Scholar 

  • Salven P, Orpana A, Joensuu H (1999a) Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5: 487–491

    CAS  PubMed  Google Scholar 

  • Salven P, Teerenhovi L, Joensuu H (1999b) A high pretreatment serum basic fibroblastic growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood 94: 3334–3339

    CAS  PubMed  Google Scholar 

  • Salven P, Orpana A, Teerenhovi L, Joensuu H (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: a single-institution's study of 200 patients. Blood 94: 3334–3339

    Google Scholar 

  • Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C (1998) Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 92: 360–363

    CAS  PubMed  Google Scholar 

  • Ugurel S, Pappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19: 577–583

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Azienda Ospedaliera ‘Pugliese-Ciaccio’, Catanzaro, Italy

    S Molica & D Levato

  2. Department of Oncology, Azienda Ospedaliera ‘Pugliese-Ciaccio’, Catanzaro, Italy

    S Molica & D Levato

  3. Clinical Pathology Service, Istituto ‘Regina Elena’ IRCCS, Roma, Italy

    G Vitelli, A Ricciotti & G Digiesi

Authors
  1. S Molica
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Vitelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Levato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Ricciotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Digiesi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Molica.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molica, S., Vitelli, G., Levato, D. et al. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer 86, 31–35 (2002). https://doi.org/10.1038/sj.bjc.6600022

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bjc.6600022

Keywords

This article is cited by

Search

Advanced search

Quick links